As a historical SPAC, Helix Acquisition was sponsored by Cormorant Asset Management and focused on healthcare sector targets. The vehicle successfully deployed capital into immunotherapy, though it is now defunct as a standalone acquisition entity.
Cyborg Score Rationale
This entity is no longer an active SPAC and has been fully merged. It cannot be evaluated as an ongoing business. All HLXA shareholders received equity in MoonLake Immunotherapeutics upon closing.
Top Insights
HLXA completed business combination with MoonLake Immunotherapeutics on April 5, 2022, and the SPAC entity was dissolved.
Cormorant Asset Management sponsored both the original Helix Acquisition (HLXA) and Helix Acquisition Corp. II (HLXB).
The HLXA sponsor went on to establish Helix Acquisition Corp. III (HLXC) in January 2026, demonstrating continued SPAC activity by the sponsor.
HLXA originally traded on NASDAQ as a shell company before merger completion.
Recent Developments
(April 2022) Business combination closed; HLXA converted to MoonLake Immunotherapeutics
Open the full interactive Helix Acquisition Corp. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.